Omalizumab for treating severe persistent allergic asthma

  • Technology appraisal guidance
  • TA278
  • Published: 
Download guidance (PDF)

Appendix B: Sources of evidence considered by the Committee

A The assessment report for this appraisal was prepared by the Centre for Reviews and Dissemination/Centre for Health Economics Technology Assessment Group, University of York:

  • Norman G, Faria R, Paton F et al. Omalizumab for the treatment of severe persistent allergic asthma: a systematic review and economic evaluation, April 2012

B The following organisations accepted the invitation to participate in this appraisal as consultees and commentators. They were invited to comment on the draft scope, assessment report and the appraisal consultation document (ACD). Organisations listed in I and II were also invited to make written submissions and have the opportunity to appeal against the final appraisal determination.

I Manufacturers/sponsors:

  • Novartis

II Professional/specialist and patient/carer groups:

  • Asthma UK

  • British Society for Allergy and Clinical Immunology

  • British Thoracic Society

  • Primary Care Respiratory Society

  • Royal College of Nursing

  • Royal College of Paediatrics and Child Health

  • Royal College of Pathologists

  • Royal College of Physicians

  • Royal Pharmaceutical Society

III Other consultees:

  • Department of Health

  • Welsh Government

IV Commentator organisations (without the right of appeal):

  • Commissioning Support Appraisals Service

  • Department of Health, Social Services and Public Safety for Northern Ireland

  • Healthcare Improvement Scotland

  • Medicines and Healthcare products Regulatory Agency

  • MRC and Asthma UK Centre in Allergic Mechanisms of Asthma

C The following individuals were selected from clinical specialist and patient expert nominations from the non‑manufacturer/sponsor consultees and commentators. They participated in the Appraisal Committee discussions and provided evidence to inform the Appraisal Committee's deliberations. They gave their expert personal view on omalizumab by attending the initial Committee discussion and/or providing written evidence to the Committee. They were also invited to comment on the ACD.

  • Dr Shuaib Nasser, Consultant Physician in Allergy and Asthma, nominated by the British Society for Allergy and Clinical Immunology – clinical specialist

  • Professor Graham Roberts, Professor/Honorary Consultant in Paediatric Allergy and Respiratory Medicine, nominated by the British Society for Allergy and Clinical Immunology – clinical specialist

  • Emily Humphreys, Policy and Public Affairs Manager, Asthma UK nominated by Asthma UK ‑ patient expert

  • Stewart Thompson, nominated by Asthma UKK – patient expert

  • Nicola Whitehead, nominated by Asthma UKK – patient expert

D Representatives from the following manufacturers/sponsors attended Committee meetings. They contributed only when asked by the Committee chair to clarify specific issues and comment on factual accuracy.

  • Novartis